Related Experiment Video
Updated: Sep 30, 2025
12:16
Porphyromonas gingivalis as a Model Organism for Assessing Interaction of Anaerobic Bacteria with Host Cells
Published on: December 17, 2015
26.6K
Lenabasum Reduces Porphyromonas gingivalis-Driven Inflammation
Fareeha Batool1,2, Pierre-Yves Gegout1, Céline Stutz1,2
1Faculté de Chirurgie-Dentaire, Université de Strasbourg, 8 rue Sainte-Elisabeth, 67000, Strasbourg, France.
Inflammation
|March 11, 2022
Summary
Lenabasum demonstrates anti-inflammatory and bone-healing effects against Porphyromonas gingivalis-induced inflammation. This synthetic cannabinoid analog shows potential for periodontal disease treatment by reducing inflammation and promoting bone repair.
Area of Science:
- Oral biology and immunology
- Pharmacology and drug discovery
- Periodontal disease research
Background:
- Porphyromonas gingivalis (Pg) infection triggers significant inflammation and bone resorption in periodontal disease.
- Lenabasum, a synthetic cannabinoid analog, possesses known anti-inflammatory properties relevant to various inflammatory conditions.
Purpose of the Study:
- To investigate the anti-inflammatory and anti-resorptive potential of lenabasum in a Porphyromonas gingivalis-induced inflammation model.
- To evaluate lenabasum's efficacy in promoting bone healing and resolving inflammation in vivo.
Main Methods:
- In vitro: Cytocompatibility assays on oral cells (epithelial cells, fibroblasts, osteoblasts) and RTqPCR analysis of inflammatory markers in Pg-infected cells treated with lenabasum.
- In vivo: Subcutaneous administration of lenabasum in a P. gingivalis-induced calvarial abscess mouse model, followed by clinical, histomorphometric, and TRAP activity assessments.
Main Results:
- Lenabasum (5 µM) was cytocompatible with oral cells and reduced pro-inflammatory markers (TNF-α, COX-2, NF-κB, RANKL) while increasing anti-inflammatory markers (IL-10, resolvin E1 receptor) in vitro.
- In vivo, lenabasum (30 µM) significantly reduced lesion size (45%), improved bone quality, decreased soft tissue inflammation, and inhibited osteoclastic activity.
Conclusions:
- Lenabasum exhibits significant anti-inflammatory and pro-resolutive effects in managing P. gingivalis-induced inflammation.
- These findings suggest lenabasum holds promise as an adjunctive therapy for periodontal disease, warranting further investigation.
